OSE Immunotherapeutics Says Tedopi Combinations Meet Phase 2 Trial Primary Endpoint
OSE Immunotherapeutics said Tedopi combinations met the primary endpoint in a Phase 2 lung cancer trial.
Related stories
Murray Cod Australia Posts Q1 FY27 Sales Volume of 175.9 Tonnes
L impact | EQUITY | Oct 30, 2026, 01:26 AM UTC
Shenzhen Composite Opens 2.1% Lower at 2069.73
M impact | EQUITY | Oct 30, 2026, 01:26 AM UTC
Daewoo Engineering & Construction Wins 275 Billion Won Order
M impact | EQUITY | Oct 30, 2026, 01:26 AM UTC
Shanghai Composite Opens 1.25% Lower at 3,605.65
M impact | EQUITY | Oct 30, 2026, 01:26 AM UTC
Civmec Reports Q1 Revenue of A$324 Million
Civmec reported Q1 FY27 revenue of A$324 million.
M impact | EQUITY | Oct 30, 2026, 01:25 AM UTC
Firstwave Cloud Technology Reports Quarterly Revenue of A$1.90 Million
M impact | EQUITY | Oct 30, 2026, 01:25 AM UTC